ADP355, designed in 2011 by Otvos and colleagues, exhibits the same effect of adiponectin in several conditions including renal and liver fibrosis, prostate and breast cancers, where it increases AMPK and STAT3 phosphorylation in MCF-7 ERα-positive breast cancer cells and inhibits the phosphorylation of ERK1/2 in MDA-MB-231 ERα-negative breast cancer cells [97]. Here, ESR1 is linked to breast carcinoma.